INTERVENTIONALPROTOCOL REGISTERED2019-003919-53
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN ADULT PATIENTS WITH PRIMARY PR...
Primary Progressive multiple sclerosis
Locally preserved from EU Clinical Trials Register (EudraCT)Open EU Clinical Trials Register (EudraCT)↗last source update not reported
What this record can show
Protocol only - no registry results posted
This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.
Registry facts
Study at a glance
- Phase
- Not reported
- Enrollment
- Not reported
- Start date
- 2020-09-23
- Sponsor
- F. Hoffmann-La Roche Ltd
- Design
- Not reported
- Locations
- 0
- Results record
- Not present in registry snapshot
Primary Progressive multiple sclerosisPrimary Progressive multiple sclerosis
Linked local records
Related local records
Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.
Cannabinoids and active compounds
No governed compound link was found.
Medicines
No exact medicine-name link was found.
Interventions
What was registered
No structured intervention was reported.
Eligibility
Population and criteria
- Sex
- Not reported
- Minimum age
- Not reported
- Maximum age
- Not reported
- Healthy volunteers
- Not reported
No structured eligibility criteria were reported.
Publications
Locally readable linked articles
No exact PMID-linked public article is currently readable locally.
Snapshot provenance
- Snapshot
- 1b0f1feb-9c91-4258-a06a-44fe7439b66b
- Retrieved
- 14/09/2026, 12:10:42
- SHA-256
- 50e426ffd14e55ce5cd299f06db336e5c981d8a7a41ce3955d0e4ed6b3c24798